Openbookopenbook
Equity
InMode Ltd(INMD)
USD --+0.00%
Reward52Moderate
Risk32Moderate
📊75%Data
Strong 25% profit margin
INMD
+0.0 · +0.00%
USD · NASDAQ
InMode Ltd | Healthcare
Deep Value
Market Cap:884.49M
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
32
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on INMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $16.80.

What is InMode Ltd?

designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.

INMD · Verdict

Moderate reward · moderate risk

INMD stands out on balance sheet and cash flow, but watch the volatility signal.

Based on 88% data coverage

INMD · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet100/100

    Current ratio 9.88

  • Cash flow89/100

    23% free-cash-flow margin

  • Valuation80/100

    P/E 8.7× · PEG 2.90

  • Profitability71/100

    25% net margin · 14% ROE

Watchouts 2

  • Volatility5/100

    Weak vs peers

  • Growth34/100

    Rev -6.6% CAGR · earnings -16.6%

Model-based scoring. For information only — not financial advice.

What is InMode Ltd?

designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 884.49M, and a P/E ratio of 9.8x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with valuation and profitability offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap884.49M
P/E Ratio9.7622
Dividend YieldN/A
52 Week High19.78
52 Week Low13.14
Last AnnualDecember
IPO Date8/8/2019
IncorporatedUSA
Shares Outstanding63M
No. of Employees660
IndustryMedical Devices
ExchangeNASDAQ
Beta2.17
CurrencyUSD
Websitewww.inmodemd.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.